Your browser doesn't support javascript.
loading
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Caffo, Orazio; Frantellizzi, Viviana; Monari, Fabio; Sbrana, Andrea; Costa, Renato Patrizio; Pinto, Carmine; Tucci, Marcello; Baldari, Sergio; Facchini, Gaetano; Bortolus, Roberto; Alongi, Filippo; Alongi, Pierpaolo; Palermo, Antonio; Fanti, Stefano; Biasco, Elisa; Murabito, Alessandra; Filice, Angelina; Zichi, Clizia; Pignata, Salvatore; Borsatti, Eugenio; Salgarello, Matteo; Spada, Massimiliano; Cortesi, Enrico; Vincentis, Giuseppe De.
  • Caffo O; Department of Medical Oncology, Santa Chiara Hospital, Largo Medaglie d'Oro, 38122, Trento, Italy.
  • Frantellizzi V; Department of Radiological, Oncological & Anatomo-Pathological Sciences, La Sapienza University, Viale del Policlinico 155, 00161, Rome, Italy.
  • Monari F; Department of Radiotherapy, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti, 9, 40138, Bologna, Italy.
  • Sbrana A; Department of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 67, 56126, Pisa, Italy.
  • Costa RP; Department of Nuclear Medicine, Policlinico Universitario, Via del Vespro, 129, 90127, Palermo, Italy.
  • Pinto C; Medical Oncology Unit, Clinical Cancer Centre, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.
  • Tucci M; Department of Medical Oncology, Cardinal Massaia Hospital Corso Dante Alighieri, 202, 14100, Asti, Italy.
  • Baldari S; Department of Biomedical & Dental Sciences & Morphological & Functional Images, University of Messina, Via Consolari Valeria 98125, Messina, Italy.
  • Facchini G; Department of Medical Oncology, S.M. delle Grazie Hospital, Via Domitiana, 80078 Pozzuoli (NA), Italy.
  • Bortolus R; Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via F. Gallini 2, 33081, Aviano, Italy.
  • Alongi F; Advanced Radiation Oncology Department, IRCCS Ospedale Sacro Cuore Don Calabria, Via Don A. Sempreboni, 5, 37024, Negrar, Italy.
  • Alongi P; Department of Radiological Sciences, Nuclear Medicine Service, Fondazione Istituto G. Giglio, Via Pisciotto, 90015, Cefalù, Italy.
  • Palermo A; Department of Nuclear Medicine Oncology, Santa Chiara Hospital, Largo Medaglie d'Oro, 38122, Trento, Italy.
  • Fanti S; Department of Nuclear Medicine Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti, 9, 40138, Bologna, Italy.
  • Biasco E; Azienda Ospedaliera Toscana Nord Ovest, UO Oncologia medica, Sezione Piombino/Elba, via San Rocco, Portoferraio Isola d'Elba, Italy.
  • Murabito A; Department of Nuclear Medicine, Policlinico Universitario, Via del Vespro, 129, 90127, Palermo, Italy.
  • Filice A; Department of Nuclear Medicine, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento, 80, 42123 Reggio Emilia, Italy.
  • Zichi C; Department of Medical Oncology, San Luigi Gonzaga Hospital, Regione Gonzole, 10, 10043, Orbassano, Italy.
  • Pignata S; Department of Biomedical & Dental Sciences & Morphological & Functional Images, University of Messina, Via Consolari Valeria 98125, Messina, Italy.
  • Borsatti E; Department of Nuclear Medicine, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via F. Gallini 2, 33081, Aviano, Italy.
  • Salgarello M; Department of Nuclear Medicine Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Via Don A. Sempreboni, 5, 37024, Negrar, Italy.
  • Spada M; Department of Medical Oncology, Fondazione Istituto G. Giglio, Via Pisciotto, 90015, Cefalù, Italy.
  • Cortesi E; Department of Radiological, Oncological & Anatomo-Pathological Sciences, La Sapienza University, Viale del Policlinico 155, 00161, Rome, Italy.
  • Vincentis G; Department of Radiological, Oncological & Anatomo-Pathological Sciences, La Sapienza University, Viale del Policlinico 155, 00161, Rome, Italy.
Future Oncol ; 17(7): 807-815, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33508980
Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p < 0.0001). Conclusions: Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Óseas / Radio (Elemento) / Radiofármacos / Antagonistas de Receptores Androgénicos / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Óseas / Radio (Elemento) / Radiofármacos / Antagonistas de Receptores Androgénicos / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2021 Tipo del documento: Article